ID   MEL2
AC   CVCL_RU21
SY   MEL-2; PureStem MEL2, NCr-fac progenitor; ACTC268
DR   Wikidata; Q54905154
RX   Patent=US8685386;
RX   PubMed=18462054;
WW   http://www.esibio.com/purestemr-mel2-ncr-fac-progenitor/
CC   Group: Patented cell line.
CC   From: ESI BIO - BioTime, Inc. (ES Cell International); Alameda; USA.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11150.
CC   Characteristics: Undergoes chondrogenesis in a progenitor with markers of head and limb mesenchyme and low levels of hypertrophic marker COL10A1.
CC   Derived from site: In situ; Blastocyst; UBERON=UBERON_0000358.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9773 ! WA09
SX   Female
AG   Blastocyst stage
CA   Somatic stem cell
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 6
//
RX   Patent=US8685386;
RA   West M.D., Sternberg H., Chapman K.B.;
RT   "Methods and compositions for in vitro and in vivo chondrogenesis.";
RL   Patent number US8685386, 01-Apr-2014.
//
RX   PubMed=18462054; DOI=10.2217/17460751.3.3.287;
RA   West M.D., Sargent R.G., Long J., Brown C., Chu J.-S., Kessler S.,
RA   Derugin N., Sampathkumar J., Burrows C., Vaziri H., Williams R.,
RA   Chapman K.B., Larocca D., Loring J.F., Murai J.T.;
RT   "The ACTCellerate initiative: large-scale combinatorial cloning of
RT   novel human embryonic stem cell derivatives.";
RL   Regen. Med. 3:287-308(2008).
//